OncoMatch/Clinical Trials/NCT06059469
PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
Is NCT06059469 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for tnbc - triple-negative breast cancer.
This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: FOLH1 imaging-defined expression
PSMA-PET/CT to assess the expression of specific membrane antigen (PSMA)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: investigational agent
Treatment by another molecule that is the object of investigation within 30 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06059469 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Does this trial require FOLH1?
Yes, FOLH1 imaging-defined expression is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify